Lymphoma Clinical Trials

Showing 2601-2620 of 3,379 trials

Study Evaluating Duvelisib in Japanese Subjects With Relapsed or Refractory Lymphoma

NCT02598570

This study seeks to evaluate the safety and pharmacokinetics of duvelisib in Japanese participants with relapsed or refractory lymphoma.

Lymphoma

AbbVie7 participantsStarted Nov 2015

Aichi, Japan • Fukuoka, Japan • Tokyo, Japan

TERMINATEDNA

Lactobacillus in Preventing Infection in Patients Undergoing a Donor Stem Cell Transplant for Hematologic Cancer or Myelodysplastic Syndrome

NCT00946283

RATIONALE: Probiotics, such as Lactobacillus, may be effective in preventing infections in patients with suppressed immune systems. PURPOSE: This phase I trial is studying the side effects and how well giving enteral nutrition, including Lactobacillus, works in preventing infections in patients undergoing donor stem cell transplant for hematologic cancer or myelodysplastic syndrome.

Breast CancerChronic Myeloproliferative DisordersLeukemia+7 more

Rutgers, The State University of New Jersey30 participantsStarted Mar 2010

New Brunswick, New Jersey, United States

COMPLETED

Mediastinal Grey Zone Lymphoma From the LYSA

NCT03037177

Mediastinal grey zone lymphoma, B cell lymphomas with intermediate features between classical Hodgkin lymphoma and primary mediastinal B cell lymphoma, are not well described in the literature. Investigators report the clinical characteristics and outcomes of a large retrospective series of 99 cases centrally reviewed by a panel of hematopathologists, with a consensus established for the diagnosis.

Mediastinal Grey Zone Lymphoma

Hospices Civils de Lyon99 participantsStarted Jan 2013

Pierre-Bénite, Auvergne-Rhône-Alpes, France

Study Evaluating Duvelisib in Japanese Subjects With Relapsed or Refractory Lymphoma

Lactobacillus in Preventing Infection in Patients Undergoing a Donor Stem Cell Transplant for Hematologic Cancer or Myelodysplastic Syndrome

Mediastinal Grey Zone Lymphoma From the LYSA

Related Searches

Rituximab, Lenalidomide, and Bortezomib in Mantle Cell Lymphoma

Observational Study of Lenalidomide in Subjects With Mantle Cell Lymphoma Who Failed Ibrutinib Treatment

Study of the Bruton's Tyrosine Kinase (BTK) Inhibitor Ibrutinib in Participants With Relapsed or Refractory Mantle Cell Lymphoma

A Study of the HSP90 Inhibitor AUY922

The Study of Pegylated Liposomal Doxorubicin Contrast Epirubicin for the Treatment of Diffuse Large B-cell Lymphoma

Safety Study of HBI-8000 in Japanese Patients With Non Hodgkin's Lymphoma

Peripheral Blood Stem Cell (PBSC) Mobilization in Patients With Relapsed Lymphoma Treated With Bendamustine

Iodine-131 Anti-B1 Antibody Consolidation for Patients With Non-Hodgkin's Lymphoma Following First-line CHOP

Expanded Access Study Of BEXXAR® For Low Grade And Transformed Low-Grade Non-Hodgkin's Lymphoma

Retreatment of Patients With Non-Hodgkin's Lymphoma Who Have Previously Responded to Iodine-131 Anti B1 Antibody

Clinical Study With Blinatumomab in Patients With Relapsed/Refractory Diffuse Large B-cell Lymphoma (DLBCL)

Erythropoietin in the Treatment of Anemia After Autologous Hematopoietic Stem Cell Transplantation

Gleevec in Relapsed/Refractory T Cell Non-Hodgkin's Lymphoma

A Study of Treatment ALK(+) Systemic Anaplastic Large Cell Lymphoma With Crizotinib

A Open Label Phase I/II Clinical Trial to Evaluate CPI-613 in Patients With Advanced Malignancies

Salvage Therapy With Chemotherapy and Natural Killer Cells in Relapsed/Refractory Paediatric T Cell Lymphoblastic Leukaemia and Lymphoma

Fludarabine Plus Octreotide in Treating Patients With Relapsed Low-Grade Non-Hodgkin's Lymphoma